2022
Induction of the activating transcription factor-4 in the intratumoral CD8+ T cells sustains their viability and anti-tumor activities
Lu Z, Bae E, Verginadis I, Zhang H, Cho C, McBrearty N, George S, Diehl J, Koumenis C, Bradley L, Fuchs S. Induction of the activating transcription factor-4 in the intratumoral CD8+ T cells sustains their viability and anti-tumor activities. Cancer Immunology, Immunotherapy 2022, 72: 815-826. PMID: 36063172, PMCID: PMC10317204, DOI: 10.1007/s00262-022-03286-2.Peer-Reviewed Original ResearchConceptsActivity of CD8Tumor-derived factorsT cellsTumor microenvironmentTranscription factor 4Anti-tumor immunityImmune suppressive factorsFactor 4Anti-tumor activityFunction of ATF4Anti-cancer therapyIntratumoral CD8Cytotoxic CD8Immune therapyTherapeutic regimensAntigenic stimulationCD8Suppressive factorsT lymphocytesMouse modelImpaired activationWild-type counterpartsSelective ablationTherapyInduction of ATF4
2021
Regulation of intercellular biomolecule transfer–driven tumor angiogenesis and responses to anticancer therapies
Lu Z, Ortiz A, Verginadis I, Peck A, Zahedi F, Cho C, Yu P, DeRita R, Zhang H, Kubanoff R, Sun Y, Yaspan A, Krespan E, Beiting D, Radaelli E, Ryeom S, Diehl J, Rui H, Koumenis C, Fuchs S. Regulation of intercellular biomolecule transfer–driven tumor angiogenesis and responses to anticancer therapies. Journal Of Clinical Investigation 2021, 131: e144225. PMID: 33998600, PMCID: PMC8121529, DOI: 10.1172/jci144225.Peer-Reviewed Original ResearchConceptsTumor growthEndothelial cellsMetastatic diseaseAnticancer therapyPoor disease outcomeColorectal cancerIntratumoral angiogenesisAngiostatic effectsDisease outcomeTherapeutic effectSide effectsOverall efficacyPharmacologic inhibitionTumor angiogenesisCH25HTherapyBenign cellsAngiogenesisDiseaseLow levelsCellsRegimensPatientsReserpineCancer
2019
An Interferon-Driven Oxysterol-Based Defense against Tumor-Derived Extracellular Vesicles
Ortiz A, Gui J, Zahedi F, Yu P, Cho C, Bhattacharya S, Carbone CJ, Yu Q, Katlinski KV, Katlinskaya YV, Handa S, Haas V, Volk SW, Brice AK, Wals K, Matheson NJ, Antrobus R, Ludwig S, Whiteside TL, Sander C, Tarhini AA, Kirkwood JM, Lehner PJ, Guo W, Rui H, Minn AJ, Koumenis C, Diehl JA, Fuchs SY. An Interferon-Driven Oxysterol-Based Defense against Tumor-Derived Extracellular Vesicles. Cancer Cell 2019, 35: 33-45.e6. PMID: 30645975, PMCID: PMC6336114, DOI: 10.1016/j.ccell.2018.12.001.Peer-Reviewed Original ResearchConceptsTumor-derived extracellular vesiclesMelanoma lung metastasisPre-metastatic nicheLung metastasesAdjuvant melanoma therapyAnti-hypertensive drugsUse of reserpineExtracellular vesiclesType I interferon receptorMelanoma patientsPoor prognosisCH25HMelanoma therapyIFN receptorInterferon receptorMetastasisNormal cellsHealthy cellsReceptorsUptakeCellsPatientsPrognosisReserpineTherapy